Arthralgia in 329 Patients Taking Aromatase Inhibitors
نویسندگان
چکیده
منابع مشابه
Aromatase inhibitors and arthralgia: a growing pain?
In the current issue of ONCOLOGY, Henry et al comprehensively review the current state of knowledge regarding the incidence and pathogenesis of aromatase inhibitor (AI)-associated arthralgia, and its potential implications in terms of delivering adequate, effective adjuvant therapy. It has clearly been demonstrated in several large adjuvant trials that the addition or substitution of AIs provid...
متن کاملManagement of aromatase inhibitor–induced arthralgia
Aromatase inhibitors (AIs) are commonly used as adjuvant treatment in postmenopausal women with hormone receptor-positive early breast cancer. With both steroidal and nonsteroidal AIs, AI-induced arthralgia is frequently observed. The mechanism of AI-induced arthralgia remains unknown, and the data available from clinical trails using AIs are limited. We review the pertinent information from a ...
متن کاملAromatase inhibitor-induced arthralgia: a review.
Though aromatase inhibitors (AIs) are an essential part of estrogen receptor-positive (ER+) breast cancer therapy, many patients discontinue the medicine before their adjuvant therapy is completed because of the arthralgia which often accompanies the medicine. Up to half of women on AI therapy experience joint pain, and up to 20% will become non-compliant with the medicine because of the joint ...
متن کاملCurrent management of aromatase inhibitor-induced arthralgia.
Aromatase inhibitors (AIs) are standard of care in the adjuvant setting of postmenopausal women with hormone receptor positive breast cancer. Despite their beneficial effects on survival outcomes in breast cancer, AIs-induced arthralgia (AIA) is a common side effect which may lead to drug discontinuation and decreased AIs adherence among patients. So far, the exact pathophysiology of AIA is sti...
متن کاملManaging arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study
BACKGROUND In order to reduce the risk of recurrence, adjuvant treatment with an aromatase inhibitor (AI) is recommended for postmenopausal women following surgery for hormone receptor-positive breast cancer. AIs are associated with improved disease-free survival compared with tamoxifen. The adverse events associated with AIs resemble those of menopause, such as bone density loss and musculoske...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Breast Care
سال: 2009
ISSN: 1661-3805,1661-3791
DOI: 10.1159/000236050